Our Perspectives
THREAD Blog
Factors Shaping Study Timelines: Screenshots, Localized Content, and the Complex Role of IRB Submission Timing
Imagine a time when Sponsors and CROS can manage the study submission process without any dependencies on external parties. Having part of a process dependent on external parties adds risk and undue pressure on all parties and ultimately impacts patients who are waiting for the treatments that are to be tested.
How a Decentralized Clinical Trial Model Can Enhance Diversity in Oncology Research
The main difference between oncology research and every other therapeutic research area is that for a cancer patient, a clinical trial is the only option left after standard of care options are exhausted. The unfortunate fact is that most cancer patients still do not have access to clinical trials as further hope for treatment because of where they live.
Increasing Diverse Clinical Populations: Race & Ethnicity
The lack of representation and diversity in medical research is partially driven by a lack of access to clinical trials. Studies with limited diversity can create significant limitations on the conclusions drawn from study data. Attracting a diverse population of patients for a clinical trial is critical for patient health and long-term community wellness.
5 Ways You Can Shorten Clinical Study Timelines
In this global pressure cooker, reducing study times while meeting heightened expectations for data depth and quality is a monumental task. However, certain targeted and intentional changes can have a big impact on the overall trial duration. Here are five ways you can shorten study timelines:
How to Navigate the Global DCT Landscape
One of the benefits of running a decentralized clinical trial (DCT) is its scalability on a global level. Global adaptation of decentralized clinical trials allows sponsors and CROs to maximize operational efficiency, engage with a wide swath of participants and improve study outcomes